Abstract : Dissymmetric cross metathesis of alkenes as a convergent and general synthetic strategy allowed for the preparation of a new small series of human histone deacetylases (HDAC) inhibitors. Alkenes bearing Boc-protected hydroxamic acid and benzamide and trityl-protected thiols were used to provide the zinc binding groups and were reacted with alkenes bearing aromatic cap groups. One compound was identified as a selective HDAC6 inhibitor lead. Additional biological evaluation in cancer cell lines demonstrated its ability to stimulate the expression of the epithelial marker E-cadherin and tumor suppressor genes like SEMA3F and p21, suggesting a potential use of this compound for lung cancer treatment. Molecular docking on all 11 HDAC isoforms was used to rationalize the observed biological results.
https://www.hal.inserm.fr/inserm-02265954
Contributor : Elizabeth Bernardo
<>
Submitted on : Tuesday, August 13, 2019 - 8:24:01 AM
Last modification on : Tuesday, August 20, 2019 - 1:20:28 AM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
